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Minireview
Using genomics to deliver natural products from symbiotic
bacteria 
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Abstract
The availability of some natural products with promising anticancer activity has been limited
because they are synthesized by symbiotic bacteria associated with specific animals. Recent
research has identified the clusters of bacterial genes responsible for their synthesis, so that the
molecules can be synthesized in alternative, easily cultured bacteria. 
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Natural products in chemistry and biology
Natural products - small molecules derived from living
organisms - have long been objects of fascination and utility,
and they have provided most of the motivation for developing
organic chemistry [1]. An example is given by morphine, the
most active of the sleep-inducing compounds in opium,
which was isolated in pure form in 1806 but was known thou-
sands of years earlier [2]. Collaboration between chemists
and biologists led to the identification of the opioid receptor
and the isolation of its endogenous ligands (enkephalins).
The story of morphine and related compounds has been
repeated many times, and natural-products research still
contributes important small molecules to medicine. Between
2000 and 2003, 15 new drugs derived from natural products
were introduced for the treatment of disorders such as
malaria, fungal infections, bacterial infections, cancer, blood
clots, premature labor, infertility, and stimulation of the
central nervous system, such as Alzheimer’s disease [3,4].
Two recent papers [5,6] describe the identification and
cloning of genes encoding the biosynthetic pathway of
patellamide, a  potential anticancer agent, highlighting the
profound changes that genomic approaches are bringing
about in what is arguably the oldest scientific discipline. 
Natural-products research was transformed in the 1940s by
the establishment of the actinomycete group of Gram-positive
filamentous soil bacteria as the premier source of medically
useful natural products. The actinomycete group produces
the antibiotics streptomycin, actinomycin, erythromycin,
and vancomycin; the antifungal agents nystatin and
amphotericin; the anticancer agents doxorubicin and
calicheamicin; the immunosuppressive agents FK506 and
rapamycin; and many other useful molecules. In addition to
their ability to produce this staggering array of important
natural products, the biosynthetic genes of bacteria have an
organization that has greatly simplified genetic studies: all of
the instructions for making a product from simple metabolites
- and to avoid being killed by it - are usually found on a
continuous stretch of DNA, and heterologous expression of
this region in an alternative host confers biosynthetic com-
petence (for example, see [7]). This revelation undoubtedly
reflects the evolutionary history of natural-product biosynthesis
pathways: inheriting only a fraction of a pathway, or the
complete pathway without the gene encoding resistance to
the molecule produced (so that the organism risks poisoning
itself), confers no survival advantage. The clustering of
biosynthetic, resistance and regulatory genes in prokaryotic
pathways has proved to be a general rule. 
As the biosynthesis pathways were probed in greater depth,
it became clear that many bacterial natural products are
made by ‘assembly lines’ of enzymes and that the order of
assembly could be read from the order of the biosynthetic
genes [1]. Two large and related chemical families produced
by these assembly lines - the polyketides and the nonribosomal
peptides - include most of the important actinomycetedrugs. These assembly lines have been identified in many
sequenced genomes, and we now realize that there are large
numbers of ‘cryptic’ metabolites: natural products whose
existence can be inferred from genomic analysis but which
have never been isolated [8]. In one recent report [9], a
group at Ecopia Biosciences was able to predict the properties
of a natural product from the genome alone with enough
precision that it could be isolated.
Bacteria in surprising places
The structural similarity of natural products from widely
different organisms led to the suspicion that they might in
fact be produced by similar bacteria associated with the
various organisms. One example is provided by pederin
(Figure 1a), a toxic compound from the blister beetle,
Paederus fuscipes. In addition to raising the blisters that
give the beetle its name, pederin is also a powerful inhibitor
of protein synthesis and mitosis, and in some model systems
it has been shown to extend the lives of animals with tumors,
even at subnanomolar concentrations. Compounds with
very similar structures and biological activities, such as
theopederin A and mycalamide A, are found in sponges,
especially  Theonella  swinhoei (Figure 1a). If any of these
molecules were to be developed into a therapeutic agent, it
would have to be supplied either by collection from the
animal or by chemical synthesis. Isolating them from either
beetles or sponges could prove difficult, as they are minor
constituents of these animals found in inconsistent amounts;
and practical large-scale synthesis would be challenging
given their complex structures. Recent reports from the Piel
laboratory [10-12] make a convincing case that, in both beetles
and sponges, an associated bacterium - not an actinomycete
but an uncultured species of Pseudomonas - is responsible
for the biosynthesis of pederin-like compounds. 
Because the molecular structure of pederin-like compounds
suggests a polyketide-type assembly line, Piel and coworkers
[10] guessed the biosynthetic genes likely to be part of the
pathway and used PCR to clone them from the collective
DNA (beetle and associated microbes) of P. fuscipes. They
found the 54 kilobase (kb) ped cluster, which includes genes
encoding an assembly line for a mixture of polyketides and
nonribosomal peptides flanked by transposase pseudogenes.
A more detailed analysis of the cluster provided strong evi-
dence that it was from an uncultured Pseudomonas species
and that it was responsible for pederin biosynthesis. Addi-
tional evidence was provided by the tight correlations
between the ped cluster’s occurrence in an organism and
the isolation of pederin from that organism. A similar
approach starting with the collective DNA from T. swinhoei
revealed an almost complete biosynthetic pathway for the
shared part of the pederin-like molecules [11]. Comparison
of the genes for the putative biosynthetic pathways from the
two organisms [12] added confirmatory evidence that the
true biosynthetic pathways had been identified. Although the
combined evidence - gene analysis, correlation of pederin
production and the ped cluster, and sequence comparison
of the two pathways - made a strong case that the pathway
had been identified, the failure to identify or culture the
bacterial symbiont and the inability to express the pathway
heterologously in an alternative host left the story incom-
plete. The problem of providing a reliable supply of a poten-
tially useful therapeutic compound thus remained unsolved
by this work. 
Completing the story
Two independent recently published papers from the
Schmidt [5] and Jaspars [6] groups now couple the isolation
of a pathway with the production of a small molecule. The
patellamides and related molecules (Figure 1b) were isolated
from ascidians - sac-like, marine, filter-feeding chordates -
because of the pronounced anticancer activity of these
compounds in biological assays. The compounds almost
certainly originate from eight amino acids (for patellamide A
the sequence is Ile-Ser-Val-Cys-Ile-Thr-Val-Cys or a cyclic
permutation thereof; see Figure 1b). Ascidians, which
produce a number of cyclic peptides and cyclic-peptide
derivatives with potentially useful biological activity, harbor
obligate cyanobacterial symbionts, species in the Prochloron
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Figure 1
Structures of the main natural products discussed in this article.
(a) Representative molecules that were originally isolated from beetles
(pederin) or sponges (theopederin A and mycalamide A). They are
biosynthesized by an uncultured symbiotic bacterium, most likely a
Pseudomonas species, in both animal species. (b) Representative
patellamide molecules that were originally isolated from ascidians. The
amino acids from which each part of patellamide A are derived are
indicated. They are made by Prochloron didemni, a cultured and genome-
sequenced symbiotic cyanobacterium.
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(b)genus, which could produce some or possibly all of the
compounds isolated from ascidians.
The Schmidt laboratory [5] originally pursued an approach
similar to that used by Piel and colleagues [10-12] (Figure 2a).
Prochloron cyanobacteria were isolated from their ascidian
host (Lissoclinum patella) and used to prepare genomic
DNA. The isolates consisted primarily (> 95%) of Prochloron
didemni as judged by light microscopy. A search of predicted
protein sequences for examples of the nonribosomal adenyla-
tion domain - a highly conserved and repetitive domain
found in enzymes of the nonribosomal-peptide biosynthetic
assembly line - yielded only a single candidate gene, and
further analysis of its sequence indicated that the encoded
protein was unlikely to function in patellamide biosynthesis.
If the patellamides are not made by a nonribosomal peptide
assembly line, they must be made by ribosomal synthesis of a
precursor peptide followed by fusion of side chains with the
main chain to form small five-member rings and joining the
two ends to form a large ring (Figure 1b). 
Finding a nonribosomal peptide assembly line is relatively
straightforward as much is known about them, but finding a
ribosomal (or possibly some other) biosynthetic pathway is
much more challenging. The entire P. didemni genome was
sequenced by The Institute for Genomic Research to three-
fold coverage, and a gene cluster that could, in principle,
produce patellamide A through ribosomal translation was
identified by searching for the eight possible peptides
whose cyclization and subsequent alteration could generate
patellamide A (Figure 2a). A single coding sequence was
identified (patE,  encoding a 77 amino-acid precursor
peptide), and the same sequence also encoded the eight
residues needed to form patellamide C, which invariably is
found with patellamide A. Genes for the entire pathway
(patA-G) surrounded the patE  gene. In a decisive experi-
ment, the pathway was heterologously expressed in
Escherichia coli, and patellamides A and C were isolated
from the culture medium; there is thus no doubt that the
correct pathway has been identified. Now that the genes for
the biosynthetic pathway are known, the timing and mecha-
nism of the various steps can be analyzed.
Whereas Schmidt and colleagues [5] relied on whole-
genome sequencing, the Jaspars laboratory [6] used shotgun
cloning and heterologous expression, an approach that had
earlier been used to identify new biologically active small
molecules from cultured and uncultured bacteria [13-17].
A genomic library of cyanobacterial DNA isolated from the
same ascidian as was used by Schmidt and colleagues
(L. patella) but from a different location was used to construct
a bacterial artificial chromosome (BAC) library in E. coli
(Figure 2b). Attempts to identify clones containing nonriboso-
mal peptide-synthase genes using Southern hybridizations
revealed nothing useful, so the library was interrogated
directly for the production of patellamides using liquid chro-
matography coupled with mass spectrometry (LC-MS).
Eventually a single transformant that produced patellamide D
was identified (Figure 2b). Because the article by Jaspars
and colleagues [6] was rushed into publication to be roughly
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Figure 2
The two approaches discussed in this article for identifying the biosynthetic pathway of patellamide and expressing it in an alternative host bacterium.
(a) Schmidt and colleagues [5] used an approach of complete genome sequencing, followed by sequence analysis to identify the biosynthetic pathway,
cloning of the pathway into a heterologous host, and isolating the small molecule. (b) Jaspars and colleagues [6] used shotgun cloning of genomic DNA
followed by screening of the resulting clone library for patellamide production. These steps could, in principle, be followed by sequencing the pathway, a
step not reported by Jaspars and colleagues [6].
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(b)contemporaneous with the report by Schmidt et al. [5], no
sequence information is available. 
The two different approaches, complete genome sequencing
[5] and shotgun cloning [6], have led to roughly equivalent
results and have shown clearly that the patellamides are pro-
duced by a cyanobacterial symbiont through a pathway that
can now be studied in great depth. What are the implications
for natural products in general and what might we expect in
the future? One obvious lesson is that DNA-based approaches
have become powerful tools for finding biosynthetic path-
ways, both for the detailed analysis of their mechanistic
details and for the production of natural compounds that
would otherwise be difficult to obtain. We can confidently
expect to see a great deal of similar work in the future. A
subtler change could be a reorientation of natural-products
research, a discipline that still retains vestiges of 19th-
century exploration and natural philosophy, into a discipline
focused on genes. Finally, the challenge of using the same
approaches [5,6,10-12] to discover new natural products can
now be faced with greater confidence. 
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